Sovateltide is a first of its kind drug to treat acute cerebral ischemic stroke that can be administered up to 24 hours after the onset of symptomsIndia is the first global territory where Tyvalzi™ (Sovateltide) is being introduced WILLOWBROOK, Ill., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Pharmazz, Inc.

Sovateltide是第一种治疗急性脑缺血性中风的药物，可以在症状出现后24小时内给药。India是Tyvalzi的第一个全球性领域™ （Sovateltide）正在伊利诺伊州WILLOWBROOK推出，2023年9月14日（GLOBE NEWSWIRE）-Pharmazz，Inc。

(“Pharmazz” or the “Company”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced that it has entered into a license agreement with Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) to commercialise a first-in-class innovative drug, Tyvalzi™ (Sovateltide) in India.

（“Pharmazz”或“Company”）是一家生物制药公司，致力于开发和商业化新型疗法，以治疗重症监护患者，宣布已与Sun Pharmaceutical Industries Limited（路透社：Sun.BO，彭博：SUNP-IN，NSE:SUNPHARMA，疯牛病：524715，“Sun Pharma”，包括其子公司和/或关联公司）签订许可协议商业化一流的创新药物Tyvalzi™ （Sovateltide）在印度。

Developed by Pharmazz for potential global use, Sovateltide is indicated for treating cerebral ischemic stroke. As per agreement terms, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi™ (Sovateltide). Pharmazz will be entitled to upfront and milestone payments, including royalties.

由Pharmazz开发的潜在全球用途，Sovateltide适用于治疗脑缺血性中风。根据协议条款，Sun Pharma被授予以Tyvalzi品牌在印度销售Sovateltide的权利™ （Sovateltide）。Pharmazz将有权获得前期和里程碑付款，包括版税。

Kirti Ganorkar, CEO – India Business, Sun Pharma said, “The Phase 3 clinical trial for Tyvalzi™ conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke. Tyvalzi™ is a first-in-class innovative drug which can help improve the quality of life of stroke patients.

Sun Pharma首席执行官-印度业务Kirti Ganorkar说：“Tyvalzi的3期临床试验™ 在印度进行的研究表明缺血性卒中的神经学结果在统计学和临床​​上有意义的改善。Tyvalzi™ 是一流的创新药物，可以帮助改善中风患者的生活质量。

The drug can be administered within 24 hours for the treatment of ischemic stroke. The current treatment options provide a narrow time window of 4-5 hours limiting its use in most patients.” Dr. B. S. Paul, a leading neuro-physician at Dayanand Medical College & Hospital, Ludhiana, who was a part of the clinical trials of Tyvalzi™ (Sovateltide), said, “No new.

该药物可在24小时内用于治疗缺血性中风。目前的治疗方案提供了4-5小时的狭窄时间窗口，限制了其在大多数患者中的使用。”作为Tyvalzi临床试验的一部分，Ludhiana Dayanand医学院和医院的主要神经科医生B.S.Paul博士™ （Sovateltide）说：“没有新的。